New drug NAV-240 put to the test in healthy volunteers
NCT ID NCT06933043
First seen Jan 05, 2026 · Last updated May 15, 2026 · Updated 21 times
Summary
This early-stage study tested the safety of a new drug, NAV-240, in 24 healthy adults. Participants received multiple doses of either the drug or a placebo. The main goal was to see what side effects occurred and how the drug moved through the body. This study did not aim to treat any disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Nucleus Network
Brisbane, Queensland, 4006, Australia
Conditions
Explore the condition pages connected to this study.